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Abstract 27 
 28 
Ruminococcus gnavus is a human gut symbiont which ability to degrade mucins is mediated 29 
by an intramolecular trans-sialidase (RgNanH). RgNanH comprises a GH33 catalytic domain 30 
and a sialic acid binding carbohydrate binding module (CBM40). Here we used glycan 31 
arrays, STD NMR, X-ray crystallography, mutagenesis, and binding assays to determine the 32 
structure and function of RgNanH_CBM40 (RgCBM40). RgCBM40 displays the canonical 33 
CBM40 β-sandwich fold and broad specificity towards sialoglycans with millimolar binding 34 
affinity towards α2,3- or α2,6-sialyllactose. RgCBM40 binds to mucus produced by goblet 35 
cells and to purified mucins, providing direct evidence for a CBM40 as a novel bacterial 36 
mucus adhesin. Bioinformatics data show that RgCBM40 canonical type domains are 37 
widespread among Firmicutes. Furthermore, binding of R. gnavus ATCC 29149 to intestinal 38 
mucus is sialic acid mediated. Together, this study reveals novel features of CBMs which 39 
may contribute to the biogeography of symbiotic bacteria in the gut.  40 
 41 
 42 
  43 
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Introduction  44 
The human gut microbiota encompasses a complex community of bacterial species which 45 
play a critical role in human health, through their contribution to e.g. polysaccharide 46 
digestion, immune system development, pathogen defence1. Microbiota composition varies 47 
longitudinally along the gastrointestinal (GI) tract but also transversally from the lumen to the 48 
mucosa1,2. Most gut bacteria reside in the colon, reaching 1011 to 1012 cells per gram, where 49 
they compete for dietary and host glycans3,4. A dysbiosis of the gut microbiota is associated 50 
with intestinal diseases, including cancers, infections, and inflammatory bowel diseases5-8, 51 
underscoring the importance of understanding these host-microbe interactions in order to 52 
devise novel treatment strategies.  53 
Several factors influence the biogeography of symbiotic bacteria within the gut, including the 54 
gradient and availability of glycans within discrete physical niches2,3. The mucus layer 55 
covering the GI tract is at the interface between the gut microbiota and the host5. In the 56 
colon, the mucus layer is divided into a loose outer layer providing a habitat to commensal 57 
bacteria and an inner layer adhering to the epithelium and providing protection from bacterial 58 
invasion5. The outer mucus layer hosts a distinct intestinal microbial niche9. The intestinal 59 
mucus layers are built around large highly glycosylated gel-forming mucin MUC2 (Muc2 in 60 
mouse) secreted by goblet cells10. The glycan structures present in mucins are diverse and 61 
complex and consist of four core mucin-type O-glycans containing N-acetylgalactosamine 62 
(GalNAc), galactose (Gal) and N-acetylglucosamine (GlcNAc). Mucin O-glycosylation starts 63 
with the attachment of GalNAc residues to the hydroxyl group of Ser and Thr of the protein 64 
backbone to form the Tn antigen (GalNAcα1-Ser/Thr). This glycan is then elongated into 65 
core 1 (Galβ1-3GalNAcα1-Ser/Thr, also known as Thomsen Friedenreich-TF- or T-antigen), 66 
core 2 (Galβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr), core 3 (GlcNAcβ1-3GalNAcα1-Ser/Thr) or 67 
core 4 (GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr)11. Core 3-derived O-glycans are 68 
important components of human colonic mucin-type O-glycans12. These core structures are 69 
further elongated by the addition of other carbohydrates (e.g.  N-acetyllactosamine, LacNAc) 70 
and are most commonly terminated by fucose and sialic acid sugar residues via α1–2/3/4 71 
and α2–3/6 linkages, respectively.  These oligosaccharide chains provide binding sites and 72 
nutrients to the bacteria which have adapted to the mucosal environment13,14. Reflecting the 73 
structural diversity of mucin glycans and their prime location, commensal and pathogenic 74 
microbes have evolved a range of adhesins allowing their interaction with mucus13,15. 75 
Variation in mucosal carbohydrate availability leads to variations in the composition of the 76 
resident microbiota3,16,17 and may also impact on bacterial tropism along and across the GI 77 
tract18.   78 
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Sialic acids such as N-acetylneuraminic acid (Neu5Ac) and fucose residues in terminating 79 
positions on mucin glycan chains are prominent targets for commensal and pathogenic 80 
bacteria19,20. The ratio of sialic acid to fucose increases along the GI tract, from the ileum to 81 
the rectum in humans21 and an inverse gradient occurs in mice22. Furthermore blood group 82 
Sda/Cad related epitopes, GalNAcβ1-4(NeuAcα2-3)Gal, increase along the length of the 83 
human colon12. Over 100 complex oligosaccharides can be identified in mucins from human 84 
colonic biopsies, with most mono-, di- or trisialylated23. Release of sialic acid by microbial 85 
sialidases allows bacteria to access free sialic acid for catabolism, decrypt host ligands for 86 
adherence, participate in biofilm formation, modulate immune function by metabolic 87 
incorporation, and expose the underlying glycans for further degradation10,14,19,20.  Sialidases 88 
are often associated with additional domains including carbohydrate binding modules 89 
(CBMs) such as sialic acid specific CBM4014,24 and broadly specific CBM3225. CBMs can 90 
enhance catalytic activity by concentrating the enzymes onto carbohydrate substrates26 or 91 
mediate adherence to host cells27.  92 
Ruminococcus gnavus is a prominent member of the gut microbiota of the healthy human 93 
gut28. R. gnavus utilisation of mucin is associated with the expression of an intramolecular 94 
trans-sialidase (IT-sialidase)29,30, which is proposed to play a key role in the adaptation of gut 95 
bacteria to the mucosal environment by providing 2,7-anhydro-sialic acid as a preferential 96 
source of nutrients31. The IT-sialidase from R. gnavus ATCC 29149 (RgNanH) comprises a 97 
catalytic glycoside hydrolase domain, RgGH33 and a carbohydrate binding module, 98 
RgCBM40.  99 
Here, to gain insights into the role and specificity of sialic acid recognition by R. gnavus, we 100 
employed glycan microarray, X-ray crystallography, saturation transfer difference nuclear 101 
magnetic resonance spectroscopy (STD NMR), isothermal titration calorimetry (ITC), 102 
mutational analyses, and cell/tissue binding assays to identify RgCBM40 oligosaccharide 103 
binding partners. Prominent ligands were oligosaccharides with terminal sialic acid, including 104 
those which are not substrates for RgNanH activity. We propose a novel role for CBM40 in 105 
targeting gut bacteria towards sialic acid-rich regions of the GI tract. 106 
 107 
 108 
 109 
 110 
 111 
  112 
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Results 113 
 114 
RgCBM40 belongs to the CBM40 subfamily 115 
RgCBM40 crystallised as a dimer, adopting the canonical CBM40 β-sandwich fold with six 116 
antiparallel strands on the convex face and five on the concave face (Fig. 1a, for data 117 
collection and refinement statistics, see Table 1). Electron density was observed for all 118 
RgCBM40 residues present in the construct (50–237). The sialic acid binding site is on the 119 
concave face at the dimer interface (Fig. 1b), however size exclusion chromatography with 120 
multi angle light scattering (SEC-MALS) indicated that the full-length protein, RgNanH, is 121 
monomeric in solution (Fig. 1c). The macromolecular architecture of RgCBM40 is conserved 122 
among members of the CBM40 family (Supplementary Fig. 1), with the exception of Vibrio 123 
cholerae CBM40_NanH (VcCBM40_NanH) which is proposed to be part of a separate 124 
CBM40 subfamily (Supplementary Fig. 1h)25,32. Greatest structural homology was observed 125 
to MdCBM40 NanL (RMSD: 0.3 Å) from the Macrobdella decora IT-sialidase 126 
(Supplementary Fig. 1e)33.  127 
Protein ligand complexes were achieved for both 3’SL and 6’SL (Fig. 1d and e). No 128 
significant conformational changes were observed in the binding site upon ligand binding. 129 
Definitive electron density for the Neu5Ac and galactose residues was observed in the 3’SL 130 
and 6’SL complexes. In the 6’SL complex, electron density was also observed for the 131 
glucose residues (Fig. 1e), with the lactose positioned almost perpendicular to the sialic acid 132 
(Fig. 1e). Contrastingly, for the 3’SL complex, only partial electron density was observed for 133 
the glucose residue in a single monomer (Fig. 1d), and the glucose positioning indicates that 134 
the lactose points up and away from the binding site, without further interactions with the 135 
protein. In the 3’SL complex, the lactose positioning would permit further extensions to the 136 
carbohydrate chain as would be present in more complex or anchored glycans, whereas 137 
these may be blocked in the 6’SL complex. This would provide a degree of specificity 138 
towards sialic acid linkage.  139 
Neu5Ac binds in a chair conformation (Fig. 1f and g), mimicking the solution conformation 140 
and minimizing the energetic penalty paid upon binding26. Notably, the carboxylic acid group 141 
of Neu5Ac forms electrostatic interactions with an arginine dyad, Arg204 and Arg128, 142 
mimicking the coordination observed in sialidase active sites. The C4 hydroxyl group 143 
hydrogen bonds to Lys135 and Glu126, the N-acetyl group sits in a hydrophobic pocket 144 
formed by Tyr116 and Ile95. The N-acetyl group nitrogen interacts with both Glu126 and 145 
Tyr210. Glu126, Arg128, and Arg204 make extensive interactions with the bound ligand and 146 
are conserved in all structurally characterized CBM40 sialic acid binding sites, discounting 147 
VcCBM40_NanH34 (Supplementary Fig. 2). The environment of the glycerol side-chain of 148 
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sialic acid is generally conserved across the canonical CBM40 subfamily with the rear face 149 
(C7-H and C9-H groups) residing on a hydrophobic surface formed by Ile95 and Tyr210 in 150 
RgCBM40 (Supplementary Fig. 3a). Although VcCBM40_NanH shares the CBM40 β-151 
sandwich fold (Supplementary Fig. 1), the location, orientation, and constitution of its sialic 152 
acid binding site is not conserved (Supplementary Fig. 2).  153 
 154 
Structure-based sequence alignment 155 
CBM40s associated with sialidases fall into two subfamilies, the canonical subfamily 156 
exemplified by CpCBM40_NanJ25 (which also regroups RgCBM40, CpCBM40_NanI32, 157 
SpCBM40_NanA35, SpCBM40_NanB36, SpCBM40_NanC37 and MdCBM40 NanL33),  and the 158 
Vibrio subfamily exemplified by VcCBM40_NanH34. Considerable sequence divergence 159 
between the Vibrio and canonical CBM40 types renders satisfactory alignments difficult to 160 
produce with standard tools, as also previously reported32. Here, by detailed manual 161 
inspection, paying particular attention to the limits of secondary structure elements and 162 
intervening loops, we produced an alignment of both types of CBM40 sequences showing 163 
well-conserved positions along its length, notwithstanding the Vibrio insertion (40 residues) 164 
near the N-terminus. The pairwise identities between the canonical representatives range 165 
from 21–67%, while the maximum canonical versus Vibrio identity is 17%, reflecting that 166 
CBM40s fall into two distinct groups. This highlighted conserved residues within the 167 
canonical subfamily that may be involved in binding affinity and specificity (Fig. 2). These 168 
include (RgCBM40 numbering): an arginine dyad (Arg204 and Arg128) that interacts with 169 
the sialic acid carboxylic acid group, a glutamic acid (Glu126), which hydrogen bonds to the 170 
C4 hydroxyl; and a hydrophobic surface, which accommodates the N-acetyl moiety and the 171 
hydrophobic face of the glycerol group. Tyr116, Ile95, Tyr210 contribute to the surface of an 172 
aromatic:aliphatic:aromatic twisted platform which presents the glycerol hydroxyl groups to 173 
solvent26.  174 
Bioinformatics analyses 175 
To gain further insights into the phylotypic distribution of the CBM40 domains within bacterial 176 
genomes, we performed a database search using pHMMs derived from our alignment as 177 
queries (canonical and Vibrio-type together, referred to as 'combined'; canonical only; Vibrio-178 
type only) as well as Pfam models, "Sialidase(NTD)", "Laminin_G_3", and "Sial-lect-inser" 179 
(see Methods and Supplementary Methods). Our combined model successfully identified 180 
99.9% of the CBM40 domains matched by the individual type CBM40 models (over 16,000 181 
domain hits in the whole database of around 67,000 genomes). Further analysis of the data 182 
(see Supplementary Methods) led to the identification of 51 nonredundant sequences 183 
(Supplementary Fig. 4). Of these, the canonical CBM40 domains occurred in Firmicutes 184 
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with 40 sequences, representing 18 genera or pseudogenera, divided between classes 185 
Bacilli and Clostridia, as well as Erysipelotrichi and an unclassified member of the 186 
Firmicutes; and two sequences in Actinobacteria. The Vibrio type occurred only in 187 
Gammaproteobacteria, represented by 8 sequences in five genera. The separation between 188 
the Vibrio-type sequences and canonical CBM40 sequences across bacterial genomes was 189 
also apparent from a tree representation constructed using a simple distance-based model 190 
and neighbour-joining (Fig. 3). This dichotomy was fully supported by bootstrap analysis of 191 
1,000 replicates. There was no evidence for any intermediate or other CBM40 types. Only 192 
one sequence from Actinobacillus muris containing a canonical CBM40 (confirmed by 193 
pHMMs and conserved binding residues) was shown to be part of a Gammaproteobacteria 194 
clade (all other members Vibrio type) as supported by 79% of bootstraps. Further studies 195 
may indicate whether this domain is the closest to an inferred common ancestor of the 196 
canonical and Vibrio CBM40 types. The results for co-incidence of sialidase domains clearly 197 
indicated an association with CBM40s in this set of nonredundant sequences: we detected a 198 
sialidase domain in 92% of canonical-type CBM40 and in all Vibrio type CBM40 199 
representatives.   200 
 201 
RgCBM40 preferentially binds α2,3 linked sialosides 202 
To further explore RgNanH ligand specificity, RgCBM40 and inactive mutant RgGH33 203 
D282A, were tested for binding to various sialoglycans, using a slide microarray38,39. This 204 
sialoglycan microarray presents over 60 synthetically recreated naturally-occurring 205 
oligosaccharide structures with diverse sialic acid forms, glycosidic linkages, and underlying 206 
glycans, representing a broad range of such targets38,39. Both recombinant proteins 207 
exclusively bound to glycans terminated with sialic acids (Fig. 4). They also showed distinct 208 
specificities.  RgCBM40 bound to terminal Neu5Ac, Neu5Gc, Neu5,9Ac2 and 2-keto-3 209 
deoxynonulosonic acid (Kdn) attached with α2-3, α2-6 and α2-8 linkages (Fig. 4). In 210 
contrast, RgGH33 D282A interacted weakly with a narrow spectrum of sialoglycans, mainly 211 
α2-3-Neu5Ac-containing glycans, primarily Neu5Acα3LacNAcβ (3'SLN), 212 
Neu5Acα3Galβ3GlcNAcβ, Neu5Acα3Galβ3GalNAc (STF), Neu5Acα3Lacβ (GM3), and 213 
Neu5Acα3Galβ3GalNAcβ3Lac (Fig. 4). Noticeably, RgGH33 D282A recognized some of the 214 
α2-3-linked sialoglycans but not any α2-6- or α2-8-linked ones, in line with its substrate 215 
specificity30. In marked contrast, every α2-3-linked sialyl oligosaccharide present on the 216 
array could be bound by RgCBM40. RgCBM40 showed a preference for terminal Neu5Ac 217 
over Neu5Gc, and for α2-3>>α2-6>α2-8 linkages. RgCBM40 bound generally more strongly 218 
to glycans containing LacNAc and Lac. RgCBM40 could bind Neu5Ac linked Lac with α2-3 219 
and α2-6 linkage, albeit to a lesser degree, whereas binding to Neu5Ac linked LacNAc was 220 
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α2-3-specific. Due to the glycan orientation introduced by the α2-6-sialic acid linkage the 221 
6’SL glucose residue is close to the protein surface (Fig. 1e). Therefore, α2-6-linked LacNAc 222 
N-acetyl group may be blocked by protein residues, whereas the α2-3 linked glycan would 223 
be more solvent exposed. The highest binding was to Neu5,9Ac2α3GalβR1. Interestingly, 224 
RgCBM40 bound to Neu5Gcα3Galβ3GalNAcβR1 (Neu5Gc-TF) and 225 
Neu5Gc9Acα3Galβ3GalNAcβR1 (Neu5Gc9Ac-TF) although with 5–10 fold less intensity, but 226 
it could not bind to the same ligands with the αR1 linkage. RgCBM40 bound to α2-3-227 
sialylated Lewis X (3’SLX, both Neu5Ac and Neu5Gc forms, although Neu5Ac was 228 
preferred). Sulfation of the 6 position of GlcNAc in 3'SLX (both Neu5Ac and Neu5Gc) 229 
improved binding of the protein (Fig. 4).  230 
To validate some of the glycan array data, we used STD NMR spectroscopy40,41 against a 231 
range of sialylated ligands. Since the highest STD intensities correlate with the closest 232 
ligand-protein contacts in the bound state42, STD NMR experiments provide important 233 
information on the binding epitope of the complexed ligand43.  234 
Here Neu5Ac, Neu5Gc, 2,7-anhydro-Neu5Ac, 3’SL, 6’SL, Neu5Acα3Gal (3’SGal), 235 
Neu5Acα6Gal (6’SGal), 3’SLN, Neu5Acα6LacNAc (6’SLN), Neu5Gcα3Lac (3’SLGc), 236 
Neu5Gcα6Lac (6’SLGc), Neu5Acα6GalαOC3H6N3 (Neu5Ac-STn), 237 
Neu5Gcα6GalαOC3H6N3 (Neu5Gc-STn), and STFαOC3H6N3 were tested as potential 238 
ligands for RgCBM40. With the exception of the three monosaccharides, Neu5Ac, Neu5Gc, 239 
and 2,7-anhydro-Neu5Ac, binding to RgCBM40 was detected for all di- and tri-saccharides 240 
tested. For the latter, the binding epitope mapping was obtained and analyzed as described 241 
under Methods. Fig. 5a shows the STD NMR spectra of 3’SL and 6’SL, and Fig. 5b their 242 
binding epitope mapping. The sialic acid ring was found to be the main recognition element 243 
and the binding mode was not affected by the nature of the glycosidic linkage (α2-3 or α2-6) 244 
of the sialoglycan (Supplementary Fig. 5). The same was true for the other Neu5Ac-ending 245 
ligands tested (see binding epitope mapping in Supplementary Fig. 6). The overall binding 246 
epitopes of 3’SL and 6’SL from the STD NMR in solution state are in good agreement with 247 
the crystal structures (Fig. 5), where the sialic acid is in close contact to the protein surface 248 
while the lactose moiety is solvent exposed as suggested from the very low STD intensities 249 
observed for the galactose and glucose protons. Very strong STD intensity is observed at 250 
the methyl group (Fig. 5). This is in excellent agreement with the N-acetyl group sitting in the 251 
hydrophobic pocket facing many protein protons (Hδ and Hγ) from the side chains of Ile95, 252 
Tyr116, and Tyr210 (Fig. 1f and 1g). High intensity on H7 compared to the much lower one 253 
on the adjacent H8 agrees with H7 facing the hydrophobic side chains while H8 (Fig. 5), in 254 
trans-conformation to it, is pointing towards the solvent. Within experimental error, no stark 255 
differences were observed in the orientation of the sialic acid ring in the binding pocket of 256 
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RgCBM40. RgCBM40 also showed binding to Neu5Gc-ending oligosaccharides, albeit with 257 
a lower strength. Fig. 5c shows the binding epitope of 3’SLGc and 6’SLGc (STD spectra are 258 
shown in Supplementary Fig. 6). Again, sialic acid was the main recognition element of 259 
these sialoglycans, but the binding epitope mapping was slightly different, in comparison to 260 
those of 3’SL and 6’SL. For the Neu5Gc-ending ligands, stronger STD intensities on H3s 261 
and lower ones on H6 were observed, suggesting a small reorientation of the ring around 262 
C3, which would expose C6, in order to fit the bulkier hydroxyl group on the acetamide 263 
moiety.  264 
The affinity of the interaction between RgCBM40 and sialic acid ligands was further 265 
assessed by ITC. Both 3’SL and 6’SL bound with similar low affinities, with dissociation 266 
constants of 0.57 mM and 1.70 mM, respectively (Fig. 6a and b, Supplementary Table 1). 267 
This confirms that RgCBM40 is specific for the terminal residue irrespective of the glycosidic 268 
linkage but with a slight preference (~ 3 fold) for the 2-3 linkage. Furthermore, it would 269 
suggest that the additional binding interactions observed in the crystal structure of the 270 
complex between RgCBM40 and 6’SL do not significantly promote binding, also in 271 
agreement with the STD NMR results, showing that sialic acid is the main binding epitope in 272 
solution. We confirmed that RgCBM40 binds to Neu5Gc-oligosaccharides, albeit with lower 273 
affinity, in accordance with the glycan array and STD NMR results. RgCBM40 has a Kd of 274 
~3 mM and >10 mM towards 3’SLGc and 6’SLGc, respectively (Fig. 6c, Supplementary 275 
Table 1). Very weak (~20 mM) interaction was observed between RgCBM40 and Neu5Ac 276 
(Fig. 6d) or Neu5Gc monosaccharides (Supplementary Table 1). The STD NMR 277 
experiments were carried out with 1 mM sugar, well below the Kd, which explains why no 278 
interaction was observed using this approach. Thermodynamic analysis showed that the 279 
reaction is enthalpy-driven (Supplementary Table 2). 280 
To further assess the involvement of individual residues we introduced point mutations 281 
specifically designed to abrogate CBM binding. Arg128, Arg204, Tyr116, Tyr 210, Glu126 282 
and Ile95 were chosen for alanine substitutions. Analysis of the secondary structure by 283 
circular dichroism (CD) suggests that the recombinant proteins were correctly folded 284 
(Supplementary Fig. 7). Binding to Neu5Ac, 3’SL and 6’SL was abolished for the double 285 
mutant R128A/R204A as well as all single mutants, with the exception of I95A as shown by 286 
ITC (Supplementary Fig. 8a and b, Supplementary Table 1). I95A binds 3’SL and 6’SL 287 
with a Kd of 1.82 and 1.37 mM, respectively, broadly similar to the binding of the wild type 288 
enzyme (Supplementary Table 1).This suggests that Ile95 is not an essential component of 289 
the hydrophobic pocket or the aromatic:aliphatic:aromatic twisted platform, and that the Tyr 290 
residues may compensate for the mutation of Ile95 to Ala. The binding ability of I95A to 3’SL 291 
and 6’SL was further confirmed by STD-NMR (Supplementary Fig. 9).  292 
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Taken together, the STD NMR and ITC data confirmed binding of both α2-3 and α2-6 linked 293 
sugars and raise questions regarding differences in ligand specificity between the catalytic 294 
and carbohydrate binding domains constituting RgNanH. We previously showed that 295 
RgNanH is specific for α2-3-linked substrates30. To determine the influence of RgCBM40 on 296 
the sialidase activity, we compared the enzymatic activity of RgNanH and RgGH33 on a 297 
range of sialylated substrates. The reaction was monitored by HPAEC-PAD and showed no 298 
difference in catalytic activity on short oligosaccharides 3’SL, 3’SLX (Neu5Ac form) or on 299 
large polymeric MUC2 mucins (Supplementary Fig. 10), indicating that, in the conditions 300 
tested, RgCBM40 did not potentiate the enzyme activity on these substrates. 301 
 302 
RgCBM40 is a novel bacterial mucus adhesin  303 
R. gnavus ATCC 29149 but not the E1 strain encodes the IT-sialidase required for mucin-304 
degradation29,30. Immunogold labeling and western blotting confirmed the presence of 305 
RgNanH on R. gnavus ATCC 29149 cell-surface but not E1 (Supplementary Fig. 11a and 306 
b). Given the role of RgNanH in R. gnavus mucin glycan utilization, the binding of RgCBM40 307 
was tested towards a range of mucins with different glycosylation profiles by ELISA. The 308 
sialylation level of purified commercial pig gastric mucin (pPGM), mixed and Muc2/MUC2 309 
mucins from mice and LS174T human cell line was analyzed by mass spectrometry (MS), 310 
revealing that most of the mucins tested contained >8% sialylated structures; pPGM and 311 
Muc2 from the colon of wild type C57BL/6 mice contained <2% sialylated structures whereas 312 
the level of sialylation of LS174T MUC2 reaches 91% (Supplementary Table 3).  Highest 313 
binding was observed to LS174T MUC2 whereas binding was lowest to pPGM or Muc2 from 314 
the colon of wild type mice, which contain low levels of sialylation (Fig. 7a). The interaction 315 
was dependent on the concentration of RgCBM40 (Supplementary Fig. 12). RgCBM40 316 
generally bound more strongly to mucins extracted from C3GnT-/- mice (mutants which lack 317 
core 3 β1-3-N-acetylglucosaminyltransferase, C3GnT)44 than to mucins from wild type mice. 318 
Irrespective of the mouse model, the binding of RgCBM40 to Muc2 from the small intestine 319 
was higher than from the colon (Fig. 7a). The adhesion level correlated well with the level of 320 
sialylation between the different mucins tested (r2 = 0.88; Fig. 7b). RgCBM40 bound 321 
significantly less strongly to MUC2 which has been treated with trifluoroacetic acid (TFA) to 322 
remove sialic acid, or with any of the sialidases tested which included the broad-specificity 323 
sialidase from Clostridium perfringens (Cp) and the α2-3-specific sialidases from Salmonella 324 
typhimurium (St), Akkermansia muciniphila (Ak) and R. gnavus (Rg), confirming the 325 
specificity of RgCBM40 for terminal sialic acid (Fig. 7c). Consistent with the low affinity of 326 
CBM40 for Neu5Ac, this monosaccharide had no effect on adherence of RgCBM40 to mucin 327 
(Fig. 7d). However, addition of free 3’SL or 6’SL prior to binding significantly decreased 328 
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adherence of RgCBM40 to MUC2 (Fig. 7d). These data indicate that RgCBM40 recognizes 329 
sialylated mammalian mucins.  330 
Having shown that RgCBM40 can bind to sialylated oligosaccharides and mucins, we tested 331 
its ability to bind to mucus from mouse intestinal tissue and human cell lines cells by 332 
immunofluorescence (Fig. 8). Methacarn fixation allowed preservation of mucus in both 333 
tissue sections and cell lines. Strong binding was demonstrated to mucus produced by 334 
LS174T which correlated with staining patterns of SNA (a sialic acid specific lectin) and 335 
MUC2 (Fig. 8a). No staining was observed in negative controls (RgCBM40 free). RgCBM40, 336 
Muc2 and lectin staining was also observed in crypts as well as on the epithelial surface of 337 
mouse colonic tissue (Fig. 8b). In addition, sialidase treatment of mouse colonic sections 338 
markedly reduced the binding of RgCBM40 as well as the SNA lectin control (Fig. 8c). SNA 339 
can outcompete RgCBM40 binding to the mucus layer in mouse colonic tissue sections, 340 
further indicating that the binding of RgCBM40 to mucus is sialic acid mediated (Fig. 8d). 341 
Similar inhibition was observed when using bacterial cells.  R. gnavus ATCC 29149 was 342 
shown to bind to areas that correlated with mucus staining. This binding was blocked with 343 
the addition of SNA (Fig. 8e), confirming the importance of sialic acid recognition in R. 344 
gnavus ATCC 29149 binding to mucus. 345 
 346 
Discussion 347 
Sialic acids are often found capping mammalian glycans and are thus common binding 348 
targets of commensal or invading microbes. A wide variety of microorganisms utilize CBM-349 
containing sialidases to process these terminal sialic acid residues. At present CBMs in 350 
family 40 are the only known examples to bind sialic acid and are exclusively associated 351 
with sialidases (www.cazy.org). The CBM40 from R. gnavus, RgCBM40, adopts the 352 
characteristic CBM40 β-sandwich fold, previously reported for CBM40s present in C. 353 
perfringens25, 32, V. cholerae34, M. decora33 as well as S. pneumoniae35,36,37.  354 
In their description of C. perfringens CpCBM40_NanJ, Boraston et al. pointed out that there 355 
appears to be two subfamilies within the CBM40 family, one typified by CpCBM40_NanJ and 356 
the other by V. cholerae VcCBM40_NanH25. This was further supported by phylogenetic 357 
analyses of all CBM40 structurally characterized so far32. It is clear that Vibrio sp. forms an 358 
outlying clade in the family that has very low amino acid sequence identity (<15%) with the 359 
main clade32. Here, we showed that the separation between the Vibrio-type sequences and 360 
canonical CBM40 sequences is also observed across bacterial genomes. Both types adopt 361 
a β-sandwich fold, however this is the most common core fold across CBM families26. 362 
RgCBM40 crystal structures, of the canonical type, in complex with sialylated ligands 363 
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demonstrate shared core binding site residues. In brief, on one side of the sialic acid 364 
residue, the carboxylic acid and C4 hydroxyl groups are coordinated by an arginine dyad 365 
(Arg128 and Arg204) and a glutamic acid (Glu126) residue, respectively. The importance of 366 
the arginine residues was further confirmed by mutational analyses, showing loss of binding 367 
of RgCBM40 R204A, RgCBM40 R128A and the double mutant RgCBM40 R128A/R204A to 368 
3’SL. The methyl of the N-acetyl moiety and the C-H face of the glycerol moiety reside on a 369 
hydrophobic twisted platform surface formed by primarily aromatic residues, of which Tyr116 370 
and Tyr210 are essential for binding. Glu126 was also shown to be essential, as predicted 371 
given its conservation and interactions with both the N-acetyl group N and the C4 hydroxyl of 372 
the sialic acid moiety.  373 
RgCBM40 showed broad specificity for sialylated oligosaccharides with dissociation 374 
constants to 3’SL and 6’SL in the millimolar affinity range, 0.57 mM and 1.70 mM, 375 
respectively. This is comparable to the affinity recently measured for the isolated S. 376 
pneumoniae SpCBM40_NanC37 against 3’SL (Kd ∼ 1.5 mM) and 6’SL (Kd ∼ 1.6 mM). Low 377 
sialic acid affinity has also been proposed for CpCBM40_NanJ from the C. perfringens 378 
sialidase however this was not quantified25. Micromolar sialic acid affinity has been observed 379 
for C. perfringens CpCBM40_NanI and S. pneumoniae SpCBM40_NanA32,35. Additional 380 
electrostatic interactions with the sialic acid glycerol moiety may contribute to these unusual 381 
affinities, in the case SpCBM40_NanA via the introduction of a tryptophan in place of 382 
RgCBM40 Tyr210 (Supplementary Fig. 3a, b), and in the case of CpCBM40_NanI via 383 
Asn158, which approaches the binding site from a nearby loop extension (Supplementary 384 
Fig. 3c). CpCBM40_NanI also introduces additional water mediated interactions with the 385 
galactose residues of bound 3’SL via a further loop extension (Supplementary Fig. 1h): 386 
These are proposed to provide specificity for the corresponding sialic acid linkage32. A 387 
corresponding extension is absent in RgCBM40 leading to minimal observed interactions 388 
between the protein and galactose (Fig.1f, g, Supplementary Fig 1a). Similar absence in 389 
SpCBM40_NanA suggests that these water-mediated interactions are not the defining 390 
feature of high CBM40 sialic acid affinity. 391 
Overall the binding epitopes of 3’SL and 6’SL, as determined by STD NMR, were in 392 
agreement with the crystal structure, and confirmed the flexibility of the galactose and 393 
glucose rings at the reducing end. Although the sialic acid moiety was the main recognition 394 
element for the interaction with RgCBM40, only weak binding was observed to Neu5Ac or 395 
Neu5Gc monosaccharides. Sialic acid residues present in oligosaccharides are α-anomers. 396 
However, in solution sialic acid adopts both α and β-anomeric configurations, as well as an 397 
open chain conformation, with the β-anomer forming the dominant constituent45. In the 398 
RgCBM40 complex crystal structures, sialic acid is bound in the α-anomeric conformation, 399 
13 
 
allowing the axial C2 carboxylic acid moiety to form a conserved interaction with Arg204. 400 
The RgCBM40 preference for the minority α-anomer will incur a large entropic penalty. This 401 
may provide a major contributory factor to the low observed monosaccharide affinity. 402 
Thermodynamic analysis showed that the reaction is driven by enthalpy, with unfavorable 403 
entropy (Supplementary Table 2), which is typical of interactions between CBMs and 404 
saccharides46. 405 
The binding specificity of CBMs most commonly matches that of the appended catalytic 406 
module26,47. We previously showed that the catalytic activity of RgNanH is specific for α2-3-407 
linked sialic acid30. However, our glycan array and STD NMR data clearly showed that 408 
RgCBM40 can recognize a wide range of α2-3- and α2-6-sialic acid-linked oligosaccharides 409 
which are commonly found in human GI mucins12,21,23, suggesting an additional function. 410 
More than 100 complex oligosaccharides were identified in mucins from human colonic 411 
biopsies where most were mono-, di- or trisialylated23. RgCBM40 bound Neu5Acα2-6Tn and 412 
Neu5,9Ac2α2-6Tn, Neu5Acα2-3TF and Neu5,9Ac2-TF9Ac2α2-3TF but not to the non-413 
sialylated forms; it also recognises Neu5Ac and acetylated Neu5Ac-linked Lac with α2-3 and 414 
α2-6 linkage but shows a strict preference for Neu5Ac-linked LacNAc with α2-3 linkage, in 415 
line with the increased expression of group Sd(a)/Cad related epitopes GalNAcβ1-416 
4(NeuAcα2-3)Gal along the length of the colon12. Despite the large diversity of structures, 417 
the sigmoid MUC2 O-glycan repertoire and relative amounts in normal individuals is 418 
relatively constant23, suggesting their role in selecting a specific mucus-associated 419 
microbiota.  Many bacterial species bind host tissues through protein-carbohydrate 420 
interactions via a variety of cell-surface proteins and appendages. Although a wide number 421 
of microbial lectins have been functionally and structurally characterized to date, especially 422 
from pathogens, only a few carbohydrate-binding proteins present in gut bacteria which 423 
interact with mucus have been structurally characterized13,15. Interactions between bacterial 424 
adhesins from gut commensals and mucin glycans are generally of low affinity, in line with 425 
the localization of these bacteria within the outer mucus layer48,49. Here we showed that 426 
RgCBM40 could recognize mucins with binding affinity increasing with sialic acid level. 427 
Binding was highest towards human colonic MUC2, consistent with the increasing sialic acid 428 
gradient along the GI tract from the small intestine to the colon in humans21. This study 429 
demonstrates CBM40 mediating interaction to mucus, therefore expanding the repertoire of 430 
bacterial adhesins to mucus. In addition to variations along the length of the GI tract, mucin 431 
sialylation varies significantly between species, and thus could influence host species and 432 
niche specificity of the gut symbionts. Interestingly, RgCBM40 also showed binding to 433 
Neu5Gc-containing oligosaccharides, albeit to lower affinity as compared to Neu5Ac-434 
oligosaccharides. Humans express predominantly Neu5Ac whereas Neu5Gc is expressed in 435 
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many non-human mammals50. Therefore, the ability of CBM from human gut commensal 436 
bacteria to bind to Neu5Gc was unexpected. However, it cannot be excluded that RgCBM40 437 
mediates binding to dietary Neu5Gc-containing glycoproteins51. 438 
CBMs typically function to maintain carbohydrate-active enzymes (CAZymes) in proximity of 439 
the substrate, thereby enhancing catalytic activity26,46,52,53. It has recently been suggested 440 
that CBMs may play an additional role in the host–bacterium interaction by not only 441 
mediating the attachment of CAZymes to glycans present on host tissues but by aiding the 442 
adherence of the entire bacterium27. This would be particularly relevant to bacteria of the 443 
human gut microbiota which are characterized by their large and diverse repertoires of CBM-444 
containing CAZymes54. Many CAZymes are known, or postulated to be, attached to the 445 
bacterial cell surface4. Here, immunogold labeling confirmed the presence of RgNanH on R. 446 
gnavus ATCC 29149 cell-surface but not on R. gnavus E1. In addition, we showed that the 447 
binding of R. gnavus ATCC 29149 to intestinal mucus was sialic acid mediated. The 448 
potential avidity effect of CBM40-mediated binding of sialylated mucins in vivo (when 449 
naturally present on the bacterial cell surface), may favor a mechanism by which CBM40 450 
helps targeting the bacteria towards sialic acid rich regions of the GI tract, therefore 451 
promoting bacterial colonization within the outer mucus layer. Our bioinformatics analyses of 452 
bacterial genomes showed that RgCBM40 canonical type domains are widespread among 453 
Firmicutes, also reflecting the strong difference in CAZyme content and diversity between 454 
the Firmicutes and Bacteroidetes phyla54. We thus propose a new role of CBMs in assisting 455 
the tropism and spatial distribution of symbiotic bacteria among physical niches in the gut. 456 
 457 
  458 
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Methods 459 
 460 
Materials 461 
General chemicals including Neu5Ac were from Sigma (St Louis/MOI, US). Neu5Gcα2-3Lac 462 
Neu5Gcα2-6Lac, Neu5Ac-STn, Neu5Gc-STn and STFαOC3H6N3) were synthesised 463 
following published methodology38,55.  Neu5Gc, 3’SL, 6’SL, 3’SGal, 6’SGal, 3’SLN, 6’SLN, 464 
were from Carbosynth.  2,7-anhydro-Neu5Ac was synthesised as previously reported31. 465 
Sialidase from Clostridium perfringens and Salmonella typhimurium LT2 were from New 466 
England Biolabs (Ipswich, MA US). Sialidase 0625 from Akkermansia muciniphila was a gift 467 
from WM de Vos30. Polyclonal antiserum against IMAC-purified His6-RgNanH30 was raised in 468 
rabbits by BioGenes GmbH (Berlin, Germany) and provided at a titre of >1:200 000. 469 
Protease inhibitors benzamidine, N-ethylmaleimide, PMSF, sodium azide and soy bean 470 
inhibitor were from Sigma. Fluorescein labelled Sambucus nigra lectin (SNA-FITC) 471 
biotinylated SNA (SNA-biotin) and Vectashield were from Vector laboratories (Peterborough, 472 
UK). Streptavidin Alexa Fluor 488 conjugate was Thermo Fischer Scientific (Eugene/OR, 473 
US). Deuterium oxide (99.9% 2H) and Tris(hydroxymethyl-d3)amino-d2-methane (Tris-d11, 474 
98% 2H) were from Sigma. Mouse monoclonal anti-His-HiLyte Flour 555 antibody was 475 
obtained from LifeSpan BioSciences (Seattle/WA, US). Blocking reagent was from Perkin 476 
Elmer (Boston/MA, US). Rabbit Mucin 2 antibody H-300 was from Santa Cruz (Dallas/TX, 477 
US, SC-15334), Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 488 (A11034) and 478 
Goat anti-Rabbit IgG Secondary Antibody Alexa Fluor 594 (A11037) from Thermo Fischer 479 
Scientific. DAPI was from Life Technologies, O.C.T. Compound from VWR and Hydromount 480 
from National Diagnostics (Atlanta/GA, USA). 481 
 482 
Expression and purification of RgCBM40 and RgNanH 483 
Using the full-length sequence encoding RgNanH in pOPINF from R. gnavus strain ATCC 484 
29149 as a template30, RgCBM40 (residues 50–237), RgNanH (residues 26–723) and 485 
RgGH33 (residues 243–723) were cloned into the pEHISTEV vector56 using the primers 486 
listed in Supplementary Table 4. Protein expression and purification of RgCBM40 and 487 
RgNanH was similar to that of RgGH3330. Points of divergence are indicated below. For 488 
protein expression, recombinant plasmids were transformed into E. coli BL21 Rosetta (DE3) 489 
(Novagen, NJ, US). A single colony was used to inoculate a 10 ml Luria Bertani (LB) 490 
medium pre-culture, which was incubated overnight under shaking at 200 rpm (at 30 °C for 491 
crystallisation and protein size determination or at 37 °C for all other protein assays). The 492 
pre-culture was used to inoculate 500 ml of auto induction medium (Formedium, Norfolk, 493 
UK), which was incubated under shaking at 37 °C for 3 h followed by 60 h incubation at 16 494 
°C. All cultures were inoculated with 50 µg ml-1 kanamycin.  495 
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For crystallisation and protein size determination, cells were harvested by centrifugation, 496 
resuspended in phosphate buffered saline (PBS, 150 mM sodium chloride, 10 mM sodium 497 
phosphate, pH 7.4) for RgCBM40 and in 20 mM Tris-HCl pH 7.5, 50 mM NaCl for RgNanH, 498 
supplemented with DNase I (20 µg ml-1) and cOmplete protease inhibitor mixture tablets 499 
(Roche, Welwyn Garden City, UK), and lysed using a constant flow cell disrupter. Insoluble 500 
components were removed by centrifugation and filtration through a 0.22 µm pore size 501 
syringe driven filter (Millipore, NJ, US). Soluble lysate was loaded onto a nickel-Sepharose 502 
column (GE Healthcare, Little Chalfont, UK) overnight at 4 °C. The sample was then washed 503 
extensively with lysis buffer supplemented with 5 mM imidazole for RgCBM40 and with 504 
150 mM imidazole for RgNanH and was eluted using lysis buffer supplemented with 50 mM 505 
imidazole for RgCBM40 and with 300 mM imidazole for RgNanH. The sample was then 506 
dialysed into lysis buffer and cleaved of its six-histidine tag using Tobacco Etch Protease at 507 
a mass ratio of 1:50 overnight at 4 °C. Finally, the gel filtration step using a Sephacryl S-100 508 
column (GE Healthcare) was performed using 20 Tris pH 7.5 with 50 mM NaCl. The purified 509 
RgCBM40 was crystallised as described below. To determine the size in solution of 510 
RgNanH, size exclusion chromatography with multi angle light scattering (SEC-MALS) was 511 
performed using an NGC chromatography system (Biorad, Hercules, CA,US) equipped with 512 
a DAWN HELEOS II MALS detector (Wyatt technology, Haverhill, UK) and an Optilab T-rEX 513 
differential Refractive Index detector (Wyatt Technology). The data were analysed using 514 
ASTRA (Wyatt Technology). 515 
For all other protein assays, the cell pellets were resuspended in Bug buster-HT (Merck, 516 
Kenilworth, NJ, US) with the supplied lysozyme and lysed by shaking in this solution for 1 h 517 
at room temperature. Insoluble material was removed by centrifugation at 4 °C, 3320 g for 518 
25 min and the supernatant was dialysed into desalting buffer (50 mM Tris-HCl, 150 mM 519 
NaCl, pH 7.8 containing 10 mM imidazole for RgGH33 and RgNanH and no imidazole for 520 
RgCBM40, the difference is due to the poor binding of the His6-tag of RgCBM40 to the nickel 521 
column) to remove the Bug buster-HT. Again insoluble material was removed by 522 
centrifugation as above, except at 8 000 g. Purification of the soluble lysate was loaded onto 523 
the immobilized metal ion affinity chromatography (IMAC column, His-bind, Novagen) in 524 
binding buffer (desalting buffer with the addition of 10 mM imidazole) using the Akta Express 525 
(GE Healthcare). The protein was eluted with binding buffer containing 500 mM imidazole 526 
and then immediately desalted into desalting buffer. The partially purified protein was 527 
concentrated using 3.5 kDa MWCO spin columns (Sartorius, Gottingen, Germany) prior to 528 
gel filtration again with the Akta Express in desalting buffer (see above) on a Superdex 75 529 
column (GE Healthcare). Purity of the proteins was assessed throughout by SDS-PAGE 530 
using the Novex system (Thermo Fisher Scientific).  531 
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 532 
Site-directed mutagenesis 533 
Site directed mutagenesis of RgGH33 to introduce the D282A mutation in the active site was 534 
carried out using the QuikChange kit, following the manufacturer’s instructions, Agilent 535 
(Santa Clara, CA, US). Site-directed mutants of RgCBM40; I95A, Y116A, E126A, R128A, 536 
R204A and double mutant R128A/R204A, were obtained from NZyTech (Lisbon, Portugal). 537 
The primers are listed in Supplementary Table 4. The integrity of the RgGH33 and 538 
RgCBM40 mutants was checked by circular dichroism (CD).    539 
 540 
Circular dichroism 541 
CD spectra were recorded using a JASCo J-700 spectropolarimeter, under the following 542 
conditions: 20 nm/min scan speed, bandwidth 1 nm, response 2 s, 5 points/nm and 4 543 
accumulations. Far-UV spectra (260-180nm) were recorded in a 0.1 mm pathlength cell. The 544 
spectropolarimeter was calibrated using camphorsulphonic acid (Sigma). The protein was 545 
extensively dialysed into 10 mM sodium phosphate buffer, pH 6.5 and a buffer only control 546 
was subtracted from all spectra using the molar CD factor calculated as follows: (113 x 30 x 547 
10-6)/ [conc(mg ml-1) x pathlength (cm)]. 548 
 549 
Protein crystallisation 550 
The final crystallisation condition was 0.2 M ammonium chloride with 20% PEG 8000. The 551 
drop contained 0.5 µl protein solution at 25 mg ml-1 and 0.5 µl reservoir solution, initial 552 
crystals grew in four weeks and growth time was improved significantly using micro 553 
seeding57.  Crystals were cryoprotected using the crystallisation condition supplemented with 554 
25% (w/w) glycerol. To achieve crystal structures in complex with 3’SL and 6’SL the crystals 555 
were grown in crystallisation condition supplemented with 20 mM ligand followed by a 60 556 
min soak in crystallisation condition supplemented with 100 mM ligand immediately prior to 557 
cryoprotection and mounting.  558 
 559 
Solving the crystal structure 560 
X-ray diffraction experiments were performed at 100 K. Data were collected using a Rigaku 561 
MSC Micromax 007 HF X-ray source, with a fixed wavelength of 1.542 Å, and a Saturn 944+ 562 
CCD detector. Sweeps were indexed and integrated separately and then scaled together 563 
within the HKL2000 data processing package58. Phasing was performed by Phaser59 within 564 
the CCP4 package60 using the CBM40 of the M. decora sialidase NanL (MdCBM40_NanL) 565 
(PDB 2SLI)33 as the molecular replacement model. The model was refined using iterative 566 
cycles of Refmac561 and Coot62. The PDB REDO server was used to optimize the 567 
refinement parameters63. The model was validated using the Molprobity server64. Paired 568 
18 
 
refinement performed by the PDB REDO server indicated that the models were improved by 569 
the inclusion of high resolution, low completeness data for the 3’SL and 6’SL complexes65. 570 
For an illustrative stereo image of a portion of the electron density map, see Supplementary 571 
Fig. 13. 572 
 573 
Isothermal titration calorimetry 574 
ITC experiments were performed using the PEAQ-ITC system (Malvern, Malvern, UK) with a 575 
cell volume of 200 µl. Prior to titration protein samples were exhaustively dialyzed into PBS. 576 
The ligand was dissolved in the dialysis buffer. The cell protein concentration was 115 µM 577 
(except for mutant I95A where it was 173 µM and the wild type interaction with 6’SL where it 578 
was 230 µM) and the syringe ligand concentration was 10 mM (25 mM for Neu5Ac). 579 
Controls with titrant (sugar) injected into buffer only were subtracted from the data.  Analysis 580 
was performed using Malvern software, using a single binding site model. The stoichiometry 581 
of binding sites was set to 1.0 as this was evident from the crystal structure. Quantitative and 582 
most qualitative experiments were carried out in triplicate.  583 
 584 
STD NMR experiments 585 
1H and 13C resonance assignment for all the sugars was performed on the bases of 1D 1H, 586 
2D DQF-COSY, TOCSY, HSQC and NOESY experiments run on the free ligands in 587 
unbuffered D2O, pH 7.0. For STD NMR experiments, all the samples consisted of 1 mM 588 
sialoglycans and 50 μM RgCBM40 (WT or I95A mutant) in D2O buffer solution of 10 mM 589 
Tris-d11 pH 7.8 and 100 mM NaCl (ligand : protein ratio 20 : 1). An STD pulse sequence that 590 
included 2.5 ms and 5 ms trim pulses and a 3 ms spoil gradient was used. Saturation was 591 
achieved applying a train of 50 ms Gaussian pulses (0.40 mW) on the f2 channel, at 0.60 592 
ppm (on-resonance experiments) and 40 ppm (off-resonance experiments). The broad 593 
protein signals were removed using a 40 ms spinlock (T1ρ) filter. All the experiments were 594 
recorded at 1H frequency of 800.23 MHz on a Bruker Avance III spectrometer equipped with 595 
a 5 mm probe TXI 800 MHz H-C/N-D-05 Z BTO, at 288 K. For all the sialoglycans in the 596 
presence of RgCBM40, an STD experiment with a saturation time of 2 s and a relaxation 597 
delay of 5 s was performed, as a first test for binding. For the confirmed binders, the STD 598 
NMR experiments were carried out at different saturation times (0.5, 1, 2, 3, 4 and 5 s) with 599 
1K scans and relaxation delay of 5 s, in order to obtain the binding epitope mapping. The 600 
resulting build-up curves for each proton were fitted mathematically to a mono-exponential 601 
equation (y=a*[1-exp(b*x)]), from which the initial slopes (a*b) were obtained. For each 602 
ligand, the binding epitope mapping was obtained by dividing the initial slopes by the one of 603 
the H7 proton of the corresponding sialic acid ring, to which an arbitrary value of 100% was 604 
assigned. This normalization of the STD values allows the comparison across all the 605 
19 
 
sialoglycans. 606 
 607 
Structure-based sequence alignment and bioinformatics analyses 608 
A structural alignment of RgCBM40 was carried out with all CBM40 structures available to 609 
date (see Results and Supplementary Methods). This served as a basis for producing an 610 
alignment including both canonical and Vibrio type CBM40 sequences to create a profile 611 
Hidden Markov Model (pHMM) using the HMMER3 software (http://hmmer.org/) 612 
(Supplementary Fig. 14), intended to detect both types simultaneously and ensure that hit 613 
sequences of both types are thus properly aligned for subsequent comparative analysis. 614 
Additionally, we created pHMMs corresponding to the canonical-only and Vibrio type-only 615 
CBM40 sequences of this alignment, to resolve the type of each hit. Protein domain 616 
databases such as Pfam66 currently characterize the canonical CBM40 as a sequence family 617 
belonging to a larger superfamily (“clan”), and some individual domains make good matches 618 
to more than one related family, i.e. including non-CBM40 such as "Concanavalin A-like 619 
lectin/glucanases" (in contrast, no Pfam domain clearly defines the Vibrio CBM40). We 620 
therefore also used the corresponding Pfam pHMMs, as well as our own, to search all 621 
available (177 million) protein sequences from annotated NCBI prokaryote genomes, using 622 
HMMER3. Where individual hit domains matched multiple pHMMs, we compared scores to 623 
identify and discard hits which might be better regarded as related, non-CBM40 domains. 624 
The remaining CBM40 proteins were screened for the presence of the sialidase domain 625 
(GH33) and IT-sialidase, as previously described30. We reduced this to a nonredundant set 626 
(Supplementary Methods) for further analysis. A detailed phylogenetic analysis is beyond 627 
the scope of this study, but we estimated evolutionary distances between these 51 628 
representative sequences using fprotdist in EMBASSY-PHYLIP67,68 from which the tree was 629 
calculated by neighbour-joining (fneighbor). All sites were included in the analysis, using the 630 
PMB model with a uniform rate of evolution. This was repeated on 1,000 replicate datasets 631 
produced by bootstrap resampling (fseqboot; consensus tree produced by fconsense). The 632 
figure was produced with FigTree (http://tree.bio.ed.ac.uk/software/figtree/). Bioinformatics 633 
analyses were performed using the Gut Health and Food Safety Linux servers at Quadram 634 
Institute Bioscience. 635 
 636 
Glycan microarray screening 637 
Glycan microarrays were fabricated using epoxide-derivatized slides as previously described 638 
(38). Printed glycan microarray slides were blocked by ethanolamine, washed and dried. 639 
Slides were then fitted in a multi-well microarray hybridization cassette (AHC4X8S, ArrayIt, 640 
Sunnyvale, CA, USA) to divide into 8 subarrays. The subarrays were blocked with ovalbumin 641 
(1% w/v) in PBS (pH 7.4) for 1 h at room temperature, with gentle shaking. Subsequently, 642 
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the blocking solution was removed and diluted protein samples of RgCBM40 and RgGH33 643 
D282A with various concentrations were added to each subarray. After incubating the 644 
samples for 2 h at room temperature with gentle shaking, the slides were washed. Diluted 645 
anti-His-HiLyte Flour 555 antibodies in PBS were added to the subarrays, incubated for 1 h 646 
at room temperature, washed and dried. The microarray slides were scanned by Genepix 647 
4000B microarray scanner (Molecular Devices Corp., Union City, CA, USA). Data analysis 648 
was performed using Genepix Pro 7.0 analysis software (Molecular Devices Corp.). It is 649 
important to note that glycans on the array with sialic acid O-acetyl groups undergo gradual 650 
losses of these labile ester groups. Therefore, definitive conclusions about 9-O-acetylation 651 
are only possible in instances wherein binding is exclusively to the O-acetylated sialoglycan 652 
spot, and not to the corresponding non-O-acetylated spot. 653 
 654 
RgCBM40 binding to mucus-producing cells 655 
The binding of RgCBM40 to mucus-producing LS174T cell line (80% confluent, passage 12) 656 
was performed by incubating the cells with 150 µg ml-1 RgCBM40 in cell culture medium for 657 
2 h at 37 °C. Control samples were incubated with cell culture medium only. The cells were 658 
then washed with PBS, fixed in methacarn (60% dry methanol, 30% chloroform and 10% 659 
acetic acid) and washed in PBS containing 0.05% bovine serum albumin (BSA).  Blocking 660 
was done with TNB buffer (0.5% w/v blocking reagent in 100 mM Tris-HCl pH 7.5, 150 mM 661 
NaCl) supplemented with 5% goat serum. The RgCBM40 binding was detected with custom-662 
made rabbit RgNanH antiserum diluted 1:100 in PBS and goat anti-rabbit antibody diluted 663 
1:400 in PBS. The same antibodies were used for negative control sample (RgCBM40-free). 664 
In the lectin control sample, SNA-biotin (incubated at 75 µg ml-1) was detected with 665 
streptavidin conjugate (2.5 µg ml-1). MUC2 was detected with rabbit Mucin 2 antibody diluted 666 
1:50 in PBS and goat anti-rabbit antibody diluted 1:200 in PBS. The cells were 667 
counterstained with DAPI and mounted in Vectashield. The slides were imaged using a 668 
Zeiss Axio Imager 2 microscope.  669 
 670 
RgCBM40 and R. gnavus binding to intestinal tissue 671 
To assess the binding of RgCBM40 to intestinal tissue sections, colon of wild type C57BL/6 672 
mouse was washed with PBS, fixed in methacarn, embedded in O.C.T. compound and cut 673 
into 8 µm sections. Access to mouse tissues was carried out under the Animal Welfare and 674 
Ethical Review Body of University of East Anglia’s establishment licence (according to Home 675 
Office requirements).  Tissue sections were washed in PBS containing 0.05% BSA and 676 
blocked with TNB buffer (0.5% w/v blocking reagent in 100 mM Tris-HCl pH 7.5, 150 mM 677 
NaCl) supplemented with 5% goat serum. The slides were then washed in PBS 0.05% BSA, 678 
followed by 2 h incubation of 150 µg ml-1 RgCBM40 in PBS at 37 °C. Control tissue sections 679 
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were incubated in PBS only. After washes in PBS with 0.05% BSA, the binding of RgCBM40 680 
was detected with custom-made rabbit RgNanH antiserum (diluted 1:100 in TNB buffer) and 681 
goat anti-rabbit antibodies (diluted 1:200 in PBS). Negative control sample (RgCBM40-free) 682 
was also incubated with these primary and secondary antibodies. Muc2 was detected with 683 
Mucin 2 antibody diluted 1:100 in TNB buffer and goat-anti rabbit antibody diluted 1:200 in 684 
PBS. In lectin controls SNA-FITC was incubated at 4 µg ml-1. The sections were 685 
counterstained with DAPI and mounted in Hydromount mounting medium. The slides were 686 
imaged using Zeiss an Axio Imager 2 microscope. To assess the binding specificity of 687 
RgCBM40 to sialylated structures, the tissue sections were pre-treated with sialidase. 688 
Briefly, saponification was performed to make the enzymatic digestion of mouse colonic 689 
tissue sections effective69. The sections were treated with 0.5% KOH in 70% ethanol for 15 690 
min at room temperature. After three PBS washes, 500 U ml-1 sialidase from Clostridium 691 
perfringens in GlycoBuffer 1 (New England Biolabs) was added and incubated for 14 h at 37 692 
°C. Sections were incubated in sialidase-free GlycoBuffer 1 under the same experimental 693 
conditions and used as a control of sialidase digestion to assess the binding RgCBM40 and 694 
SNA to tissue sections as described above.    695 
To assess the binding of R. gnavus to intestinal tissue sections, colon of wild type C57BL/6 696 
mouse was washed with PBS, fixed in methacarn, embedded in O.C.T. compound and cut 697 
into 12 µm sections. Tissue sections were washed in PBS, then incubated with SNA in PBS 698 
at 20 μg ml-1 for 1 h. Prior to incubation with bacteria, the slides were washed with PBS. R. 699 
gnavus ATCC 29149 was cultured anaerobically in BHI-YH media for 24 h as previously 700 
described29. The culture was then then used to inoculate YCFA media supplemented with 701 
3’SL at a concentration of 7 mg ml-1, and cultured for 20 h. The bacteria were then washed 702 
twice with fresh YCFA, and resuspended at an OD of 1. The tissue sections were then 703 
transferred in a humid chamber to the anaerobic cabinet, and the bacteria incubated on the 704 
sections for 1 h at 37oC. The slides were then washed twice with YCFA and fixed with 4% 705 
paraformaldehyde in PBS for 15 min. The slides were transferred out of the anaerobic 706 
cabinet, then washed with PBS and blocked with TNB buffer (0.5% w/v blocking reagent in 707 
100 mM Tris-HCl pH 7.5, 150 mM NaCl) supplemented with 5% goat serum. The presence 708 
of R. gnavus and Muc2 was detected with custom-made rabbit RgNanH antiserum (diluted 709 
1:100) and Mucin 2 antibody (1:100), respectively. Goat anti-rabbit antibodies (diluted 1:500) 710 
were used for immunodetection. The sections were counterstained with DAPI and mounted 711 
in Prolong gold anti-fade mounting medium. The slides were imaged using Zeiss an Axio 712 
Imager 2 microscope, using a x63 objective. 713 
 714 
Mucin purification 715 
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Culture media from LS174T cell line were freeze-dried before extraction of MUC2. After 716 
freeze-drying, samples were solubilised overnight in 6 M guanidine chloride (GuCl) buffer 717 
containing protease inhibitors (7.95 mM EDTA, 12.25 mM benzamidine, 6.25 mM N-718 
ethylmaleimide, 1.25 mM PMSF, 3.75 mM sodium azide, 0.1 mg/ml soy bean inhibitor). 719 
Samples were centrifuged at 18 500 g. The pellet was reduced with dithiothreitol (DTT) at 10 720 
mM for 4 h at 45 °C and alkylated with 25 mM iodoacetamide overnight before dialysis 721 
against 50 mM ammonium bicarbonate. The same protocol was followed for purifying 722 
mucins from the scraped mucus from small intestine and colon of mouse models. The 723 
supernatants containing soluble mucins were diluted in 4 M guanidinium chloride (GuCl) with 724 
phosphate buffered saline (PBS) and adjusted with cesium chloride at 1.4 g ml-1 density. 725 
Supernatants were subjected to an ultracentrifugation (Beckman, Brea, US) at 234 000 g for 726 
72 h at 20 °C. Fractions of 1 ml were collected and weighed. Fractions between 1.35 and 727 
1.45 g ml-1 were kept and dialysed against 50 mM ammonium bicarbonate. These fractions 728 
contained the purified mucins. 729 
 730 
Release of oligosaccharides from mucin  731 
The mucins were subjected to β-elimination under reductive conditions (0.1 M sodium 732 
hydroxide, 1 M sodium borohydride) for 20 h at 45 °C. The reaction was stopped by adding 733 
Dowex 50 x 8 (Sigma) and filtered before being co-evaporated with methanol 3 times. 734 
Remaining salts were removed by Carbograph (Grace, Columbia, US). 735 
 736 
Permethylation of O-glycans 737 
Permethylation was performed on released O-glycans from the different mucins samples. 738 
Samples were solubilized in 200 μl dimethyl sulfoxide. Then sodium hydroxide (trace of 739 
powder) and 300 μl iodomethane were added in anhydrous conditions and the samples 740 
vigorously shaken at room temperature for 90 min. The permethylation reaction was stopped 741 
by addition of 1 ml acetic acid (5% vol/vol). Permethylated O-glycans were purified on a 742 
Hydrophilic-Lipophilic Balanced (HLB) Oasis cartridge (Waters, Milford, US). Briefly, 743 
cartridges were activated by methanol, equilibrated with methanol:water (5:95, vol:vol), and 744 
samples loaded onto the cartridges. Cartridges were washed by methanol:water (5:95, 745 
vol:vol) and the permethylated O-glycans eluted by methanol. 746 
 747 
Analysis of permethylated O-glycans by mass spectrometry 748 
MALDI-TOF and TOF/TOF-MS data were acquired using the Bruker Autoflex analyzer mass 749 
spectrometer (Applied Biosystems, Foster City, CA, US) in the positive-ion and reflectron 750 
mode by using 2,5-dihydroxibenzoic acid (DHB; Sigma; 10 mg ml-1 in 70:30 methanol:water) 751 
as the matrix. The relative quantification of sialylation on mucins was calculated based on 752 
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the sum of all areas of mass peaks corresponding to sialylated structures divided by the sum 753 
of all areas of mass peaks corresponding to defined O-glycans. 754 
 755 
Enzyme Linked Immunosorbent Assay  756 
RgCBM40 binding to purified mucins was tested by ELISA.  Mucins (100 μl of 10 μg ml-1) 757 
were immobilised onto a high binding 96 well plate (Greiner, Stonehouse, UK) overnight at 4 758 
°C. All subsequent steps were carried out for 1 h at room temperature. The plates were 759 
blocked with 3% (w/v) BSA, incubated with RgCBM40 (500 μg ml-1), followed by an 760 
incubation with 1:5 000 anti-RgNanH (raised in rabbit, Biogenes) then with 1:5 000 anti-761 
rabbit secondary antibody (raised in donkey) conjugated to peroxidase (GE Healthcare). 762 
Between each step the plate was washed with 3 x 300 ul of PBS containing 0.05% (v/v) 763 
Tween 20 (PBST). Prior to detection, an additional wash step and 30 sec incubation with 764 
PBST was carried out. Binding was detected using tetramethylbenzidine (TMB) visualisation 765 
solution (Biolegend, San Diego, CA, US) which was incubated for 15 min. The reaction was 766 
stopped by addition of 2 M H2SO4 and absorbance measured at 450 nm using a plate-reader 767 
(Bench Marl Plus, Biorad), subtracting background readings at 570 nm. Negative controls 768 
including no RgCBM40 (subtracted from A450 value), no primary or no secondary antibody 769 
were carried out in parallel. For comparison between plates, values were normalised to the 770 
reading for LS174T MUC2 which was arbitrarily set at 100%. For enzymatic treatment of the 771 
mucin, LS174T MUC2 (2 mg ml-1) was incubated with sialidases (2 µg ml-1) overnight at 4 °C 772 
on a rotary wheel prior to immobilization on the plate. For chemical treatment of mucin, 773 
LS174T MUC2 was incubated with 0.1 M trifluoroacetic acid (TFA) at 80 °C for 1 h, dialysed 774 
against ammonium bicarbonate (50 mM), lyophilised and redissolved in H2O. For the 775 
competition assays, RgCBM40 was incubated with 1 mM of free sugar overnight at 4°C on a 776 
rotary wheel prior to addition to the ELISA plate as above. Experiments were carried out in 777 
triplicate.  778 
 779 
HPAEC-PAD analyses 780 
The substrates, 3’SL (500 μM, 8.5 nM enzyme), 3’SLX (Neu5Ac form), 500 μM, 80 nM 781 
enzyme) or LS174T MUC2 (0.9 mg ml-1, 1.5 nM enzyme) were incubated with RgNanH or 782 
RgGH33 at 37 °C in 20 mM sodium phosphate buffer, pH 6.5. BSA (0.1 mg ml-1) was 783 
included in the oligosaccharide reactions. Control reactions without enzyme were also 784 
carried out in parallel. Aliquots of reaction were removed and the reaction terminated by 785 
boiling for 20 min. For LS174T MUC2, the released sugars were removed using 5 kDa 786 
MWCO spin columns and the remaining mucin subjected to acid hydrolysis; the samples 787 
were incubated with 0.1 M HCl at 80 °C for 1 h, dried under vacuum and resuspended in 788 
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H2O at 1 mg ml-1. The amount of Neu5Ac remaining on the mucin was quantified by 789 
comparing the peak size for Neu5Ac with an internal standard of 2-keto-3-deoxynononic acid 790 
(Kdn). The reaction products for all substrates were filtered with 0.22 μm spin tubes prior to 791 
analysis by HPAEC-PAD (Dionex ICS-5000, Thermo Fisher Scientific). An internal standard 792 
of fucose (50 μM) was used for 3’SL and 3’SLX. For 3’SL, a Carbo-Pac PA1 column 793 
(Thermo Fisher Scientific) was used with a 6 min isocratic gradient of 100 mM sodium 794 
hydroxide, 100 mM sodium acetate followed by a 10 min washing step with 100 mM sodium 795 
hydroxide, 200 mM sodium acetate and 10 min re-equilibration with 100 mM sodium 796 
hydroxide, 100 mM sodium acetate. For 3’SLX, a Carbo-Pac PA100 was used with 5 min at 797 
100 mM sodium hydroxide, a gradient of 0–50 mM sodium acetate over 5 min, followed by a 798 
gradient of 50–225 mM sodium acetate. The column was then cleaned with 500 mM sodium 799 
acetate for 5 min and re-equilibrated for 15 min at 100 mM sodium hydroxide. For analysis of 800 
the acid hydrolysis products of MUC2, a Carbo-Pac PA10 was used with a gradient of 70–801 
300 mM sodium acetate with 100 mM sodium hydroxide over 10 min, a brief (1 min) period 802 
of 300 mM sodium acetate followed by a decrease (over 1 min) to 70 mM sodium acetate 803 
and 15 min re-equilibration at 70 mM sodium acetate. All columns were protected with their 804 
respective guard columns, except for the mucin analysis where an amino-guard column was 805 
used. 806 
 807 
Western blotting 808 
R. gnavus strains were grown to stationary phase and cells pelleted by centrifugation for 10 809 
min at 3 000 g at 4 °C. The supernatant was collected and the extracellular proteins 810 
concentrated 50-fold using a 10-kDa MWCO Amicon Ultra-0.5 Centrifugal Filter (Millipore, 811 
Watford, UK). The cell pellet was re-suspended in 20 μl PBS with an equal bead (100 μm 812 
glass beads) volume added and samples vortexed at full speed three times for 2 min with 2 813 
min rest intervals on ice. The volume was made up to 17 μl per mg wet cell weight with PBS 814 
and vortexed at full speed again for 2 min. The beads were removed by allowing them to 815 
settle under gravity and the remaining samples centrifuged for 30 min at 17 000 g at 4 °C. 816 
The supernatant containing the soluble cytosolic proteins was collected and concentrated 817 
10-fold using a 10-kDa MWCO Amicon Ultra-0.5 Centrifugal Filter. The remaining pellet was 818 
dissolved in 1.7 μl per mg wet cell weight digestion buffer (50 mM Tris-HCl (pH 8.0), 5 mM 819 
MgCl2, 5 mM CaCl2, 10 mg ml
-1 Hen Egg White Lysozyme (Sigma), and incubated at 37°C 820 
for 3 h. The samples were centrifuged for 30 min at 17 000 g at 4 °C, and the supernatant 821 
containing the cell wall associated proteins collected. Samples were analysed on duplicate 822 
NuPAGE Novex 4–12% Bis-Tris gels, one gel was stained with InstantBlue stain (Expedeon, 823 
Swavesey, UK) and the other gel blotted onto a PVDF membrane using X-cell II Blot module 824 
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(Thermo Fisher Scientific), according to manufacturer’s instructions. Membranes were 825 
blocked with 3% BSA in PBST for 3 h, and then incubated with the custom-made anti-826 
RgNanH antibody raised in rabbit diluted 1:5000 in 1% BSA in PBST overnight. Blots were 827 
washed in PBST, then incubated with anti-rabbit IgG antibody (Sigma) diluted 1:7 500 in 1% 828 
BSA in PBST for 2 h. After washing three times in PBST, the blots were incubated using a 829 
visualisation solution (10 ml of 0.1 M Tris-HCl (pH 9.6), 40 μl of 1 M MgCl2, 20 μl of nitroblue 830 
tetrazolium, and 10 μl of 5-Bromo-4-Chloro-3-Indolyl phosphate, Sigma) for up to 15 min, 831 
and washed in distilled water to stop the development of the signal. 832 
 833 
Immunogold labelling of whole bacterial cells 834 
R. gnavus strains were grown to stationary phase and cells pelleted by centrifugation for 10 835 
min at 3 000 g at 4 °C before being resuspended in PBS. A small drop of concentrated R. 836 
gnavus cell suspension was applied to a formvar/carbon coated gold TEM grid (Agar 837 
Scientific, Stansted, UK) and left for 1 min. The bacteria on the grids were vapour fixed by 838 
placing the grids in a sealed Petri dish with a small cap-full of 25% glutaraldehyde (Agar 839 
Scientific) for 2 h. The grids were floated on drops of 50 mM Glycine/PBS for 15 min 840 
followed by floating on drops of Aurion blocking buffer (Aurion, Wageningen, The 841 
Netherlands) for 30 min. The grids were then washed five times for 5 min with 0.1% BSA-C 842 
(Aurion) in PBS. Grids were incubated in anti-RgNanH antibody raised in rabbit diluted 843 
1:2000 with 0.1% BSA-C/PBS or in a control solution of 0.1% BSA-C/PBS overnight at 4°C. 844 
The grids were washed five times for 5 min with 0.1% BSA-C/PBS. Grids were then 845 
transferred to a 1/50 dilution of goat-anti-rabbit antibody conjugated with 10 nm gold balls 846 
(Agar Scientific) in 0.1% BSA-C/PBS and incubated for 2 h at room temperature. The grids 847 
were washed five times for 5 min with 0.1% BSA-C/PBS, followed by three 5 min washes in 848 
PBS only. The grids were refixed by immersing them in 2% glutaraldehyde/PBS for 1.5 h 849 
followed by three 5 min PBS washes and three 5 min distilled water washes before the grids 850 
were carefully blotted and dried. The grids were examined and imaged in a FEI Tecnai G2 851 
20 Twin transmission electron microscope at 200 kV. 852 
 853 
Statistical analysis 854 
One-way ANOVA model analyses were used to assess the binding of RgCBM40 to purified 855 
mucins by ELISA. When the effect of the factor was found to be significant (p value < 0.05) 856 
and its number of levels greater than 2, a Tukey test was used to assess the significance of 857 
the difference between multiple means. Statistical analyses were performed using the 858 
software SAS 9.4 (NC, USA). 859 
 860 
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Data availability 861 
Atomic coordinates have been deposited in the Protein Data Bank (www.rcsb.org) with 862 
accession codes: unbound, 6ER2; 3’SL bound, 6ER3, 6’SL bound; 6ER4. All other relevant 863 
data are available from the authors. 864 
 865 
 866 
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Figure Legends 1062 
 1063 
Figure 1 Crystal structure of RgCBM40 in complex with .3’SL and 6’SL (a) RgCBM40 is 1064 
shown in a cartoon representation with a rotation of 90° around the x axis. (b) The protein 1065 
crystallised as a dimer with the ligand binding site at the dimer interface. The binding sites 1066 
are shown occupied by 6’SL trisaccharides (Neu5Ac: cyan, galactose: blue, glucose: 1067 
orange). (c) SEC-MALS performed with full length RgNanH (77 kDa). The SEC-MALS 1068 
predicted molecular weight was 73 kDa, indicating that RgNanH is monomeric in solution. 1069 
Bound 3’SL (d) and 6’SL (e) are shown with their corresponding Fo-Fc omit maps at 2 σ 1070 
(light cyan), 3 σ (orange), and 5 σ (magenta). The omit maps are carved at 1.6 Å around the 1071 
bound ligand. For 3’SL, the map is carved around a dummy glucose residue to indicate the 1072 
presence of partial electron density. A close-up view of RgCBM40 binding site is shown with 1073 
(f) 3’SL and (g) 6’SL. The Neu5Ac residue is shown in cyan and the galactose residue as 1074 
black lines, for clarity the glucose residue is not shown. Interacting RgCBM40 residues are 1075 
shown in green with black dashed lines indicating hydrogen bonding interactions. A semi-1076 
transparent surface indicates the hydrophobic surface. 1077 
 1078 
Figure 2. CBM40 structural alignment  1079 
Structure-based alignment (α-helices and β-strands respectively in red and yellow) of 1080 
CBM40 domains of RgCBM40 with C. perfringens CpCBM40_NanJ (PDB code 2V73) and 1081 
CpCBM40_NanI (PDB code 5FRA), M. decora MdCBM40_NanL (PDB code 1SLI) and S. 1082 
pneumoniae SpCBM40_NanA (PDB code 4C1W), SpCBM40_NanB (PDB code 2VW0) and 1083 
SpCBM40_NanC (PDB code 4YZ5) and VcCBM40_NanH structure (PDB code 2W68). 1084 
Amino acids identified as binding sites are highlighted in blue. RgCBM40 residues Ile95, 1085 
Asp110, Tyr116, Glu126, Arg128, Arg204 and Tyr210 are at positions 104, 119, 125, 135, 1086 
137, 226 and 233 of the alignment. The alignment supplemented with other canonical and 1087 
Vibrio-type CBM40 sequences, used to create the pHMM using HMMER3, is shown in 1088 
Supplementary Fig. 4. 1089 
 1090 
Figure 3. Distance-based tree of canonical and Vibrio-type CBM40 sequences 1091 
Tree of 51 non-redundant sequences (80% identity level) calculated by neighbour-joining 1092 
using evolutionary distances estimated by applying the PMB model of amino acid changes, 1093 
including all sites and using a uniform rate of evolution. The representative sequences 1094 
corresponding most closely (at least 97% identical) to the 7 bacterial structure-determined 1095 
sequences are shown with symbols, coloured in accordance with Supplementary Fig. 1: 1096 
"A", SpCBM40_NanA; "B", SpCBM40_NanB "C", SpCBM40_NanC; "I", CpCBM40_NanI; 1097 
"J", CpCBM40_NanJ; "R", RgCBM40; "V", VcCBM40_NanH. Additionally, "L" denotes 1098 
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MdCBM40_NanL closest to the bacterial sequence of highest identity (70% identical to 1099 
RgCBM40) as only bacterial sequences were searched.  1100 
 1101 
Figure 4. Sialoglycan microarray analysis of binding specificities of RgCBM40 and 1102 
RgGH33 D282A. Binding of the recombinant proteins RgCBM40 and RgGH33 D282A at 20 1103 
and 200 µg mL-1, respectively are presented (n = 4, SD). Heat map was generated using the 1104 
method as previously described38,39. Binding was ranked as (glycan average RFU/ maximum 1105 
glycan average RFU)*100. Red and white represent the maximum and minimum, 1106 
respectively. R1 represents propyl-azide as the spacer. 1107 
 1108 
Figure 5. STD NMR analysis of RgCBM40 binding to sialoglycans, (a) Reference (top) 1109 
and difference (bottom) spectra of 3’SL and 6’SL. The strongest signals from the Neu5Ac’s 1110 
protons are labelled in the difference spectra. (b) Binding epitope mapping from STD NMR 1111 
of 3’SL and 6’SL. Legend indicates relative STD intensities normalised at H7: blue, 0–24%; 1112 
yellow, 25–50%, red 51–100%; larger red dots indicate values over 100%. Sialic acid is the 1113 
main recognition element. (c) Binding epitopes mapping from STD NMR of Neu5Gcα2-3Lac 1114 
and Neu5Gcα2-6Lac. Legend as above. Sialic acid is the main recognition element. The 1115 
strongest STD intensities from CH2 and the H3s, suggest a reorientation of the Neu5Gc ring 1116 
in the binding pocket, in comparison to 3’SL and 6’SL. 1117 
 1118 
Figure 6.  ITC isotherms of RgCBM40 to sialoglycans. (a) RgCBM40 binding to 3’SL, (b) 1119 
RgCBM40 binding to 6’SL, (c) RgCBM40 binding to 3’SLGc, (d) RgCBM40 binding to 1120 
Neu5Ac. The Kd is indicated in mM. *This value is an estimate as the Kd is too high to 1121 
determine with the concentration of sugar used. 1122 
 1123 
Figure 7. ELISA of RgCBM40 binding to purified mucins. 1124 
(a) RgCBM40 binding to a range of purified mucins; mucin 2 (MUC2) and mixed mucins 1125 
(mucins) from human cell line LS174T, purified pig gastric mucin (pPGM), and murine 1126 
mucins from germ free (GF), wild type (WT), and C3GnT-/- mice.  (b) Correlation of 1127 
RgCBM40 binding with % sialylated structure for each mucin tested. RgCBM40 was 1128 
incubated with immobilised mucins and binding determined by ELISA. The % sialylated 1129 
structures was determined by MS. (c) RgCBM40 binding to LS174T MUC2 which has been 1130 
treated chemically (TFA) or enzymatically with a sialidase from Clostridium perfringens (Cp), 1131 
Salmonella typhimurium (St), Akkermansia muciniphila (Am) or Ruminococcus gnavus (Rg) 1132 
(d) RgCBM40 binding to LS174T MUC2 in competition with sugars. RgCBM40 has been 1133 
preincubated with the indicated sugars. In all cases, RgCBM40 was incubated with 1134 
immobilised mucins and visualised by an ELISA using anti-sialidase primary antibody and an 1135 
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anti-rabbit secondary antibody conjugated to horseradish peroxidase. The enzyme was 1136 
incubated with TMB and the absorbance at 450 nm (A450) measured. The error bars show 1137 
the standard error of the mean (SEM) of three replicates. P values are indicated; NS-not 1138 
significant, *-p<0.05, **-p<0.005, ***-p<0.005.  1139 
 1140 
Figure 8. RgCBM40 binding to mucus-producing cells and intestinal tissue sections. 1141 
(a) Immunostaining pattern for RgCBM40 on LS174T cells correlated with mucin (MUC2) 1142 
and lectin (SNA) staining, all shown in green. No staining was observed in RgCBM40-free 1143 
sample (Blank). (b) Immunostaining pattern for RgCBM40 on cryosections of mouse colon 1144 
correlated with mucin (Muc2) and lectin (SNA) staining, all shown in green. No staining was 1145 
observed in RgCBM40-free sample (Blank). Cell nuclei were counterstained with DAPI, 1146 
shown in blue. (c) Sialidase pre-treatment of mouse colonic cryosections markedly reduced 1147 
the binding of RgCBM40 and SNA lectin. Cell nuclei were counterstained with DAPI, shown 1148 
in blue. (d) RgCBM40 competition assay with SNA on cryosections of mouse colon. 1149 
RgCBM40 is shown in green. Cell nuclei were counterstained with DAPI, shown in blue. No 1150 
RgCBM40 specific staining was detectable when SNA was present. (e) R. gnavus binding 1151 
competition assay with SNA on cryosections of mouse colon. R. gnavus ATCC 29149 was 1152 
incubated on sequential cryosections of mouse colon with or without SNA treatment and is 1153 
shown in red. The mucus layer is shown in green. Sequential sections were required as both 1154 
antibodies were raised in the same species. Cell nuclei were counterstained with DAPI, 1155 
shown in blue.  No R. gnavus staining was detectable when SNA was present. Appropriate 1156 
primary antibody and secondary antibody only controls are also shown underneath each 1157 
panel, showing some background staining. Scale bar: 20 μm. 1158 
 1159 
 1160 
  1161 
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Table 1. Data collection and refinement statistics. Values in parentheses refer to the highest 1162 
resolution shell. For the 3’SL and 6’SL complexes the data was over 90% complete to a 1163 
resolution of 1.85 Å and 1.56 Å respectively. 1164 
 1165 
Dataset Apo 3’SL 6’SL 
Data collection    
Spacegroup P21 P21 P21 
Cell dimensions     
a, b, c (Å) 46.7, 72.8, 51.3 48.8, 72.4 51.5 48.7, 72.2, 51.4,  
β (°) 104.9 105.1 103.9 
Resolution 50 – 1.73 (1.76 – 
1.73) 
39.48 – 1.37 (1.41 
– 1.37) 
49.91 – 1.30 (1.34 
– 1.30) 
Rmerge 0.03 (0.14) 0.04 (0.34) 0.03 (0.15) 
I / σI 47.3 (9.6) 22.9 (3.0) 32.0 (4.9) 
Completeness 91.8 (51.3) 74.5 (11.2) 83.9 (13.6) 
Redundancy 3.7 (2.4) 4.3 (2.4) 5.1 (1.4) 
  
Refinement    
Resolution 50 – 1.73 (1.76 – 
1.73) 
39.48 – 1.37 (1.41 
– 1.37) 
49.91 – 1.30 (1.34 
– 1.30) 
No. reflections 31570 51221 67097 
Rwork / Rfree 0.160/0.194 
(0.82) 
0.152/0.187 (0.81) 0.134/0.154 (0.87) 
No. of atoms 3145 3424 3704 
   Protein 2807 2850 3076 
   Ligand 0 81 123 
   Water 338 508 527 
B-factors    
   Protein 19.4 16.6 10.4 
   Ligand/ion  36.4 21.7 
   Water 28.1 31.7 27.3 
R.m.s.d 0.011 0.012 0.015 
   Bond lengths (Å) 0.011 0.012 0.015 
   Bond angle (°) 1.55 1.66 1.77 
*Values in parentheses are for the highest-resolution shell. One crystal was used for each 1166 
structure. 1167 
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Figure 7. ITC isotherms of RgCBM40 to sialoglycans. (a) RgCBM40 binding to 3’SL, (b) RgCBM40 binding 
to 6’SL, (c) RgCBM40 binding to 3’SLGc, (d) RgCBM40 binding to Neu5Ac  
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